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bstract
Since a KRAS oncogene mutation is an early event in colorectal cancer development and cigarette smoking is thought to have an effect on
arly stages of colorectal tumorigenesis, smoking, especially long-term smoking, may be associated with the risk for colorectal cancer with KRAS
ncogene mutations.
In the Netherlands Cohort Study on diet and cancer (n = 120,852 men and women), using a case–cohort design, adjusted incidence rate ratios
RR) and 95% confidence intervals (CI) were computed for colorectal tumors with wild-type and with mutated KRAS gene, and with specific
:C → T:A or G:C → A:T point mutations in KRAS, according to cigarette smoking status, frequency, duration, pack years, age at first exposure,
ears since cessation, inhalation and filter usage. After 7.3 years and excluding the first 2.3 years, 648 cases and 4083 sub-cohort members were
ncluded in the analyses.
Ex-smokers, but not current smokers, were at increased risk for colorectal cancer with wild-type KRAS gene tumors when compared with
ever smokers, albeit not statistically significant (RR 1.26, 95% CI 0.96–1.66). This was not observed for KRAS mutated tumors when comparing
x-smokers with never smokers (RR 1.15, 95% CI 0.79–1.66). The highest category of smoking frequency (>20 cigarettes/day) and inhalation of
moke were associated with an increased risk for colorectal cancer with wild-type KRAS gene tumors, though not statistically significant, when
ompared with never smoking (frequency: RR 1.24, 95% CI 0.90–1.71 and inhalation: RR 1.25, 95% CI 0.94–1.67). These associations were
trongest in men (ex-smokers: RR 1.79, 95% CI 1.00–3.20; frequency: RR 1.91, 95% CI 1.03–3.52; inhalation: RR 1.69, 95% CI 0.94–3.04). No
ssociations were observed between any of the smoking characteristics and the risk for colorectal cancer with mutated KRAS gene tumors, nor
here there any clear associations with tumors with specific G:C → A:T transitions or G:C → T:A transversions.
These results suggest that, in contrast to the hypothesis, smoking does not increase the risk for colorectal tumors with a mutated KRAS gene.
ome smoking characteristics, i.e. being an ex-smoker, frequency and inhalation, may be associated with risk for colorectal cancer characterized
y the wild-type KRAS gene, especially in men.




eywords: Smoking; Colorectal cancer; Prospective study; Netherlands Cohor
. IntroductionWith the burning of tobacco products, numerous genotoxic
ompounds are formed, including carcinogenic polycyclic aro-
atic hydrocarbons, heterocyclic amines and aromatic amines
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1]. Smoking is associated with a higher risk for cancer
n various tissues, including lung, oral cavity, pharynx, lar-
nx, pancreas, urinary bladder, renal pelvis, nasal cavities and
aranasal sinuses, nasopharynx, stomach, liver, kidney, cervix
nd esophagus [1,2]. Although associations between smoking
nd colorectal carcinomas have been inconsistent, long-term,
eavy smoking has been associated with a two- to threefold
ncreased risk for colorectal adenomas [3]. In addition, current




















































































































M.P. Weijenberg et al. / Muta
yperplastic polyps than with adenomatous polyps [4]. As most
olorectal carcinomas arise from pre-existing benign neoplasms,
he association between smoking and colorectal adenomas led to
he assumption that smoking may be involved in early tumori-
enesis. Development of colorectal cancer is thought to be a
ulti-step process which involves the accumulation of aber-
ations in a number of genes [5]. The Fearon and Vogelstein
odel assumes the involvement of the KRAS (v-Ki-ras2 Kirsten
at sarcoma viral oncogene homolog) oncogene in the transition
rom intermediate adenomas to carcinomas in sporadic colorec-
al cancer [6]. Somatic mutations can cause oncogenic activation
f KRAS. This genetic alteration occurs in adenomas as well as
n carcinomas in colon and rectal cancer. Approximately 90% of
he activating mutations are found in codons 12 and 13. The pre-
ominant mutations are G:C → A:T transitions and G:C → T:A
ransversions [7–10]. Because smoking is thought to be involved
n the early stages of colorectal tumorigenesis, smoking may
e associated with mutations in the KRAS oncogene. Results
rom rodent studies support this hypothesis: benzo(a)pyrene was
ound to induce G:C → T:A transversions and N-nitrosamines
ere found to induce G:C → A:T transitions in RAS oncogenes
11]. Both chemicals are present in tobacco smoke.
The aim of the present study is to investigate the relation-
hip between cigarette smoking and risk for overall colorectal
ancer and risk for colorectal cancer with wild-type or mutated
RAS oncogene tumors in a prospective cohort study. We stud-
ed associations between cigarette smoking and the risk for
olon, rectosigmoid and rectal cancer, with wild-type or mutated
RAS oncogene tumors within the Netherlands Cohort Study on
iet and cancer (NLCS). Additionally, we assessed associations
etween cigarette smoking and colorectal cancer with a specific
:C → T:A or G:C → A:T point mutation.
. Materials and methods
The prospective Netherlands Cohort Study (NCLS) on diet and cancer
as started in 1986. The total cohort includes 120,852 persons aged between
5 and 69 years old at baseline, of which 58,279 are men and 62,573 are
omen. The study subjects originated from 204 Dutch municipal population
egistries. In order to be included, municipalities had to satisfy two crite-
ia: (a) availability of a computerized population registry and (b) sufficient
ancer follow-up coverage. A self-administered questionnaire on diet, other
isk factors for cancer and potential confounders was completed at base-
ine [12]. The entire cohort is being monitored for cancer occurrence by
nnual record linkage to the Netherlands Cancer Registry (NCR) and Patholo-
isch Anatomisch Landelijk Geautomatiseerd Archief (PALGA), a nationwide
atabase of histo- and cytopathology reports [13]. Combining the NCR and
ALGA resulted in almost 100% coverage of the municipalities included in the
LCS.
The present analyses were carried out over the 7.3-year period of follow-
p since September 1986. Accumulation of person-time in the cohort has been
stimated through biennial vital status follow-up. A sample of 5000 men and
omen were randomly selected from the cohort after baseline exposure measure-
ent to estimate the number of personyears for the entire cohort, whereas cases
re enumerated for the entire cohort [14,15]. The sub-cohort was followed-up
iennially to assess information on vital status and migration in order to calcu-
ate accumulated person-time in the cohort. Excluded from the sub-cohort were
ases with prevalent cancer other than non-melanoma skin cancer. Because of
ncomplete nationwide coverage of PALGA alone in some of the municipalities
ncluded in the NLCS in that period and because of possible pre-clinical disease
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he period from 1989 till 1994, 925 incident cases with histologically confirmed
olorectal cancer were observed, of which 815 could be linked to a PALGA
eport of the lesion. With a PALGA report, tumor tissue form eligible colorectal
ancer patients could be located and identified in Dutch pathology laboratories.
ollection of tumor tissue specimens started in August 1999 and was completed
n December 2001. The loss to follow-up of tissue samples of cases amounted
o 5%. Colorectal cancer was classified according to site as follows: colon,
.e. cecum through sigmoid colon (ICD-O-1 codes: 153.0, 153.1, 153.2, 153.3,
53.4, 153.5, 153.6, 153.7, 153.8, 153.9), rectosigmoid (ICD-O-1 code 154.0)
nd rectum (ICD-O-1 code 154.1).
After approval by the Medical Ethical Committees (MEC) of Maastricht
niversity, PALGA and the NCR, tumor material was collected. All pathology
aboratories in the Netherlands agreed to make relevant tissue samples available
or this study. The 815 tissue samples were distributed among 54 pathology
aboratories throughout the Netherlands. Only 44 (5%) tumor tissue samples
ould not be traced. Finally, 771 (95%) of the available tissue samples were
etrieved and 734 (90%) of these contained sufficient tumor material, mak-
ng molecular analyses possible [10]. DNA isolation is described elsewhere
10]. Briefly, sections (5 m) were cut from paraffin-embedded tumor tissue
locks and stained with haematoxylin and eosin (H&E) for histopathological
xamination. Five 20-m sections of tumor tissue were used for DNA extrac-
ion. Tumor tissue was macrodissected from the normal colonic epithelium
sing the HE section as a reference. Proteinase K stock solution (20 mg/ml,
btained form Qiagen, St. Louis, MO, USA) and the Puregene® DNA Iso-
ation Kit (Gentra Systems, Minneapolis, MN, USA) were used to extract
enomic DNA from the macrodissected tumor tissue. The DNA concentra-
ion and purity were established spectrophotometrically at 260 and 280 nm
10].
Mutation analysis of the exon 1 fragment of the KRAS oncogene, spanning
odons 8–29, was performed on archival colorectal adenocarcinoma speci-
ens of 734 patients, using macrodissection, nested polymerase chain reaction
PCR) and direct sequencing of purified fragments. The detection limit was 5%
utated DNA. Duplicate experiments revealed a good reproducibility (88%)
10].
Exposure to tobacco smoke of all cancer cases and sub-cohort members was
erived from the questionnaire. Exposure to smoke from cigarettes was charac-
erized by eight smoking variables: smoking status (never, former and current),
requency, duration, pack years of smoking, age at first exposure, years since
essation, inhalation and filter usage. The never-smoker category was consid-
red to be the reference for all variables. For categorical analyses, frequency was
ivided in the categories: less than 10, 10–20 and more than 20 cigarettes smoked
er day. Duration of smoking was categorized as: less than 20, 20–40 and more
han 40 years of cigarette smoking. The variable pack-years was divided in the
ategories: less than 9, 10–30 and more than 30 pack-years of cigarette smoking.
ge at first exposure was categorized as: younger than 17, 17–21 and older than
1 years of age. Years since cessation was divided in the categories: less than
0, 10–30 and more than 30 years since cessation. Inhalation was categorized
s yes or no. Filter usage was divided in filter- and non-filter-tipped cigarette
se.
The dietary section of the questionnaire is a 150-item semi-quantative food-
requency questionnaire, which concentrated on habitual consumption of food
nd beverages during the year preceding the start of the study as well on lifestyle
actors. Questionnaires were key-entered twice and automatically coded by the
ata-entry program. Data were checked for completeness, consistency, range and
ther response errors and corrected by means of an SPSS computer program.
uestionnaires were excluded when incomplete or inconsistent. Criteria used for
his selection were (a) 60 or more questionnaire items left blank or consumption
f 35 or more food items less than once a month and/or (b) one or more item
locks (groups of items, for example beverages) left blank. Additional details
re given elsewhere [16].
The distribution of the smoking variables as well as the distributions of the
ariables sex, family history of colorectal cancer (yes/no) and physical activity
n leisure time (<30, 30–60, 60–90, >90 min/day), and the mean value of age
t baseline (years), intake of energy (kJ/day), fat (g/day), dietary fiber (g/day),
lcohol (g/day), coffee (ml/day), calcium (mg/day), vitamin A (mg/day), vita-
in C (mg/day), vitamin E (mg/day), -carotene (g/day) and body mass
ndex (BMI) (kg/m2), were evaluated for sub-cohort members and colorec-
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n the mean values of the continuous variables between patients with wild-
ype or mutated KRAS gene tumors were tested with the Student’s t-test or
ann–Whitney U test if the variables were not normally distributed. We used
he 2 test to test for differences in the distributions of the categorical variables
etween patients with wild-type or mutated KRAS gene tumors. The analyses
ere conducted separately for colorectal cancer overall, for colorectal cancer
ases with wild-type or mutated KRAS gene tumors, and for tumors with a
pecific C:G → T:A or G:C → T:A point mutation. Similar analyses were con-
ucted for different sub-sites of the colorectal tract, i.e. proximal and distal
olon cancer, rectosigmoid cancer and rectal cancer and the different molec-
lar subgroups thereof. No differences were observed between any of the
ub-sites, therefore only data of the analyses for colorectal cancer overall are
resented.
Incident rate ratios (RR) and corresponding 95% confidence intervals (CI)
or colorectal cancer cases with wild-type or mutated KRAS gene tumors were
stimated according to cigarette smoking status (never, ex, current), smoking fre-
uency (cigarettes/day), smoking duration (years), pack years, age when starting
moking (years), time since smoking cessation (years) and corresponding con-
inuous variables compared with lifelong non-smokers using Cox proportional
azards regression models with the STATA statistical software package (inter-
ooled STATA, Version 8.2). Standard errors were estimated using the robust
uber–White sandwich estimator to account for additional variance introduced
y sampling from the cohort [17]. The proportional hazard assumption was
ested using the scaled Schoenfeld residuals [18]. Tests for dose-response trends
ver the different categories of smoking variables were estimated by fitting the
rdinal exposure variables as continuous terms and evaluated using the Wald
est. Life-long non-smokers were excluded for estimation of the p-value for
rend over the categories of age when started smoking and years since smoking
essation.
All potential confounders were separately tested in the models for overall
olorectal cancer with wild-type or mutated KRAS gene tumors. Variables that
howed a ≥10% influence on the RR for cancer or were found to contribute (p-
alue < 0.10) to any of the multivariate models (age at baseline, sex), by means
f the Wald test were included in the multivariate analyses. Variables that were
dentified as confounders in the literature were also considered confounders.
inally age, sex, family history of colorectal cancer, BMI, alcohol and coffee
onsumption were considered as confounders and analyses were adjusted for
hese variables. Among all members and cases, questions on whether subjects
rank coffee were left blank by 10 persons. They were considered to be non-
rinkers. Forty-four subjects reported drinking coffee, but did not report how
uch. They were assumed to drink the mean amount of coffee consumed by the
rinkers in the sub-cohort (534 ml/day). For 143 sub-cohort members and 24
olorectal cancer cases data on BMI were missing. Data on alcohol were miss-
ng for 117 sub-cohort members and 11 colorectal cancer cases. These members
nd cases were excluded from the analyses. The Pearson correlation coefficient
etween smoking duration and smoking frequency was strong (r = 0.80). There-
ore, the variable smoking duration is not adjusted for frequency, and the variable
moking frequency is not adjusted for duration. Eventually, 648 colorectal can-
er patients (367 men, 281 women) and 4083 sub-cohort members (2031 men,
052 women) were included in the analyses.
Possible interaction by sex, alcohol, vitamin A, vitamin C, vitamin E and
-carotene was investigated by entering an interaction term in the model and
ssessing the significance of this term using the Wald test. No interactions were
bserved for any of the mentioned variables, and therefore results are shown
ombined for men and women and for the other variables. Nevertheless, since
en and women differ considerably with respect to smoking habits, analyses for
he risk of KRAS wild-type and mutated colorectal tumors according to the main
moking variables (smoking status, frequency and duration) are also presented
eparately for men and women. Finally, since ex-smokers, compared with never
mokers, appeared to be at a higher risk for cancer in some subgroup analy-
es and because current smokers were never at increased risk, analyses were
lso conducted separately for ex- and current smokers. Specifically, analyses
f the risk for KRAS wild-type and mutated colorectal tumors with frequency
nd duration of smoking are presented separately for the ex-smokers and cur-
ent smokers, using never smokers as a reference. These extra analyses are not
resented for cancers with specific mutations, since in each of these analyses
t least one of the cells contained less than 10 cases, which hampers a sound
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All p-values reported are for a two-sided test; p-values of less than 0.05 were
onsidered to be statistically significant.
. Results
Smoking habits and other baseline characteristics for sub-
ohort members and colon, rectosigmoid and rectal cancer cases
ith wild-type or mutated KRAS gene tumors are shown in
able 1. Colon, rectosigmoid and rectal cancer cases were more
ften men, were older and more frequently reported a family his-
ory of colorectal cancer compared with the sub-cohort. Colon
ancer cases with mutated KRAS tumors were significantly older,
ad higher daily intakes of vitamin E and more frequently
eported smoking both cigarettes and cigars than colon cancer
ases with a wild-type KRAS tumor, but the latter finding is based
n few cases (i.e. 17 and 18, respectively). There were no statis-
ically significant differences between colon cancer cases with
wild-type KRAS tumor and a mutated KRAS tumor in all other
actors presented in Table 1. No statistically significant differ-
nces were observed between rectosigmoid cancer cases with
ild-type KRAS tumors and mutated KRAS tumors or between
ectal cancer cases with wild-type KRAS tumors and mutated
RAS tumors for smoking and other factors. Since smoking
f cigars and pipe was rare (<1%) further data will only be
resented for cigarette smoking.
Multivariate-adjusted RR for colorectal cancer overall, col-
rectal cancer with wild-type KRAS tumors and colorectal
ancer with mutated KRAS tumors according to the smoking
ariables are presented in Table 2. The presented multivari-
te RRs are based on 648 colorectal cancer patients and 4083
ub-cohort members. Ex-smokers were at increased risk for
verall colorectal cancer compared with never smokers (RR
.22; 95% CI 0.97–1.53), but the association was not statis-
ically significant. Current smokers were not at increased risk
or overall colorectal cancer in comparison with never smokers
RR 0.81; 95% CI 0.61–1.05). There were no significant asso-
iations between smoking frequency, smoking duration, pack
ears, age at first exposure, years since cessation, inhalation
r filter usage and the risk for colorectal cancer. Associations
etween ex-smokers, smoking frequency, inhalation and the risk
or colorectal cancer with a wild-type KRAS gene appeared to
e stronger than for the risk for colorectal cancer with a mutated
RAS gene, where these associations were absent. Ex-smokers
ere at increased risk for developing colorectal cancer with
wild-type KRAS gene when compared with never smokers
RR 1.26; 95% CI 0.96–1.66), although the association was not
tatistically significant. The highest category of smoking fre-
uency (>20 cigarettes/day) and inhalation were associated with
n increased risk for colorectal cancer with a wild-type KRAS
ene, although not statistically significant (frequency: RR 1.24;
5% CI 0.90–1.71 and inhalation: RR 1.25; 95% CI 0.94–1.67).
o associations were observed between the remaining smoking
ariables, i.e. smoking duration, pack years, age at first expo-
ure, years since cessation, filter usage and the risk for colorectal
ancer with wild-type KRAS gene tumors. Regarding mutated
RAS tumors, none of the smoking variables were associated













Baseline characteristics of subcohort members, colon, rectosigmoid and rectal cancer cases with wild-type or mutated KRAS gene tumors from the NLCS after 7.3 years of follow-upa
Subcohort Colon cancer Rectosigmoid cancer Rectal cancer
Wild-type KRAS Mutated KRAS p-Valueb Wild-type KRAS Mutated KRAS p-Valueb Wild-type KRAS Mutated KRAS p-Valueb
N 4,083 288 140 42 28 87 63
Gender (% male) 49.7 51.4 58.6 0.162 52.4 57.1 0.695 72.4 57.1 0.051
Age (years, mean (S.D.)) 61.3 (4.2) 62.6 (4.1) 63.7 (3.9) 0.015 62.4 (3.9) 63.1 (4.1) 0.380 62.7 (4.0) 61.9 (3.9) 0.202
Family History of CRC (n (% yes)) 235 (5.8) 37 (12.9) 14 (10.0) 0.394 4 (9.5) 0 (0) 0.093 9 (10.3) 8 (12.7) 0.654
BMI (kg/m2, mean (S.D.)) 25.0 (3.1) 25.5 (3.2) 25.7 (3.3) 0.371 25.6 (2.6) 25.6 (3.4) 0.981 24.9 (2.9) 25.5 (2.9) 0.283
Physical activity (n, (%))
<30 825 (20.4) 56 (19.7) 32 (23.4) 6 (14.3) 4 (14.3) 17 (19.5) 16 (25.8)
30–60 1,274 (31.5) 92 (32.3) 42 (30.7) 11 (26.2) 10 (35.7) 26 (29.9) 18 (29.0)
60–90 850 (21.0) 56 (19.7) 32 (23.4) 10 (23.8) 9 (32.1) 17 (19.5) 14 (22.6)
>90 1091 (27.0) 81 (28.4) 31 (22.6) 0.481 15 (35.7) 5 (17.9) 0.421 27 (31.0) 14 (22.6) 0.625
Energy intake (kJ/day, mean (S.D.)) 8,072 (2,159) 7,982 (2,053) 80,734 (1,962) 0.661 77,078 (2,532) 8,009 (1,953) 0.597 8,404 (1,865) 8,375 (1,918) 0.925
Fat intake (g/day, mean (S.D.)) 84.1 (27.5) 83.2 (26.2) 84.7 (26.0) 0.567 82.2 (35.3) 82.3 (22.9) 0.986 85.0 (23.1) 88.4 (27.1) 0.412
Alcohol consumption (g/day, mean
(S.D.))
10.4 (14.4) 10.9 (15.4) 10.9 (14.4) 0.965 8.8 (9.0) 16.4 (16.1) 0.106 14.1 (17.9) 11.4 (12.3) 0.648
Coffee consumption (ml/day, mean
(S.D.))
538.7 (270.0) 537.5 (251.0) 541.1 (279.2) 0.919 503.0 (236.7) 517.9 (191.6) 0.652 575.1 (260.0) 584.9 (265.3) 0.966
Calcium intake (mg/day, mean
(S.D.))
926.5 (326.3) 929.6 (318.0) 910.5 (299.2) 0.553 892.6 (325.2) 828.5 (273.3) 0.393 944.4 (299.4) 866.3 (273.1) 0.104
Dietary fiber intake (g/day, mean
(S.D.))
27.0 (8.1) 26.8 (7.6) 28.1 (8.7) 0.093 27.0 (8.9) 25.7 (7.2) 0.523 27.9 (7.9) 27.7 (8.0) 0.891
Vitamin A intake (mg/day, mean
(S.D.))
1.0 (0.4) 0.9 (0.4) 1.0 (0.4) 0.820 1.2 (0.8) 0.9 (0.3) 0.185 1.0 (0.3) 1.0 (0.4) 0.880
Vitamin C intake (mg/day, mean
(S.D.))
103.7 (43.6) 102.3 (44.4) 108.1 (45.2) 0.208 118.3 (47.2) 109.0 (52.5) 0.441 110.6 (43.5) 106.5 (48.7) 0.586
Vitamin E intake (mg/day, mean
(S.D.))
13.4 (6.1) 13.3 (6.1) 14.8 (6.7) 0.024 13.5 (7.9) 13.8 (6.3) 0.852 14.1 (5.9) 14.3 (7.7) 0.859
-carotene intake (g/day, mean
(S.D.))
2,961 (1,556) 2,878 (1,305) 3,022 (1,517) 0.681 3,399 (1,614) 3,062 (1,411) 0.415 2,948 (1,225) 2,935 (1,554) 0.536
Tobacco product (n, (%))
Never smokers 1,375 (33.7) 97 (33.7) 50 (35.7) 0.678 9 (21.4) 3 (10.7) 0.244 20 (23.0) 19 (30.2) 0.323
Cigarette 2,076 (50.8) 137 (47.6) 61 (43.6) 0.436 24 (57.1) 17 (60.7) 0.766 50 (57.5) 29 (46.0) 0.166
Cigar 42 (1.0) 2 (0.7) 1 (0.7) 0.982 0 (0) 0 (0) – 1 (1.2) 0 (0) 0.393
Pipe 8 (0.2) 1 (0.4) 0 (0) 0.485 0 (0) 0 (0) – 1 (1.2) 0 (0) 0.393
Cigarette and pipe 86 (2.1) 2 (0.7) 4 (2.9) 0.074 1 (2.4) 0 (0) 0.411 2 (2.3) 3 (4.8) 0.407
Cigarette and cigar 268 (6.6) 18 (6.3) 17 (12.1) 0.037 3 (7.1) 6 (21.4) 0.080 8 (9.2) 8 (12.7) 0.493
Cigar and pipe 22 (0.5) 3 (1.0) 1 (0.7) 0.741 0 (0) 0 (0) – 0 (0) 1 (1.6) 0.238
All three products 206 (5.1) 28 (9.7) 6 (4.3) 0.051 5 (11.9) 2 (7.1) 0.515 5 (5.8) 3 (4.8) 0.791
a Numbers are based on subcohort members and patients without data missing on family history of colorectal cancer, BMI, alcohol or coffee consumption.
b p-Value for comparison between patients with wild-type and mutated KRAS gene tumors.
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Table 2
Adjusteda incidence rate ratios (RR) and corresponding 95% CI for colorectal cancer, colorectal cancer with wild-type and mutated KRAS gene tumors according to
cigarette smoking features
Cigarette smoking variable Personyears
subcohortb
Colorectal cancer Colorectal cancer–wild-type KRAS Colorectal cancer–mutated KRAS
Nc RR 95% CI Nc RR 95% CI Nc RR 95% CI
Smoking status
Never smoker 9,896 198 1.00 Reference 126 1.00 Reference 72 1.00 Reference
Ex-smoker 10,502 295 1.22 0.97–1.53 188 1.26 0.96–1.66 107 1.15 0.79–1.66
Current smoker 8,181 144 0.81 0.62–1.05 95 0.86 0.62–1.18 49 0.72 0.47–1.10
Frequency (cigarettes/day)
<10 5,002 97 0.94 0.72–1.24 63 0.98 0.70–1.36 34 0.88 0.57–1.36
10–20 6,028 142 1.08 0.82–1.42 94 1.16 0.84–1.61 48 0.93 0.60–1.46
>20 6,605 171 1.16 0.89–1.52 111 1.24 0.90–1.71 60 1.02 0.66–1.58
p-Trend 0.23 0.14 0.88
Duration (years)
<20 3,288 69 1.07 0.79–1.47 48 1.19 0.82–1.73 21 0.87 0.52–1.45
20–40 8,636 219 1.15 0.91–1.46 136 1.16 0.87–1.55 83 1.13 0.78–1.65
>40 6,389 144 0.86 0.65–1.13 94 0.93 0.67–1.30 50 0.73 0.47–1.15
p-Trend 0.43 0.76 0.33
Pack years
<9 4,905 99 1.01 0.77–1.33 66 1.07 0.77–1.84 33 0.91 0.59–1.41
10–30 7,336 169 1.04 0.80–1.36 112 1.12 0.82–1.54 57 0.91 0.59–1.39
>30 5,141 138 1.12 0.84–1.49 87 1.16 0.82–1.64 51 1.03 0.64–1.64
p-Trend 0.47 0.37 0.95
Age at first exposure (years)
<17 7,170 185 1.18 0.89–1.56 116 1.18 0.85–1.66 69 1.17 0.74–1.84
17–21 7,310 167 1.08 0.84–1.40 105 1.08 0.79–1.48 62 1.08 0.71–1.63
>21 3,980 78 0.90 0.67–1.20 54 0.99 0.70–1.39 24 0.75 0.46–1.22
p-Trend 0.45 0.84 0.27
Years since cessation (years)
<10 11,830 252 0.96 0.76–1.22 165 1.02 0.77–1.35 87 0.86 0.59–1.26
10–30 5,873 168 1.24 0.96–1.61 104 1.24 0.91–1.70 64 1.23 0.82–1.86
>30 924 17 0.78 0.45–1.33 13 0.97 0.52–1.78 4 0.47 0.17–1.32
p-Trend 0.33 0.29 0.78
Inhalation
No 5,354 107 0.90 0.69–1.17 67 0.92 0.66–1.27 40 0.86 0.56–1.31
Yes 12,874 318 1.15 0.91–1.47 209 1.25 0.94–1.67 109 0.99 0.67–1.47
Filter usage
Filter-tipped 5,043 103 1.04 0.79–1.36 66 1.05 0.76–1.46 37 1.01 0.66–1.54
Non-filter-tipped 8,892 230 1.07 0.82–1.40 148 1.12 0.82–1.53 82 1.00 0.65–1.53
























b Personyears are estimated from the subcohort.
c Missing values of smoking characteristics gave rise to diminished personye
Table 3 presents the multivariate-adjusted RRs and cor-
esponding 95% confidence intervals for colorectal cancer
atients with G:C → T:A transversions (n = 72) and patients with
:C → A:T transitions (n = 131) in KRAS in their tumors. With
egard to G:C → T:A transversions, smoking frequency was sig-
ificantly and inversely associated with the risk for tumors with
uch mutations (p = 0.03). None of the other smoking variables
ere associated with the risk for this type of tumor, but the
umber of cases in some of the smoking categories is too small
o adequately interpret the results. Regarding colorectal cancer
ith specific G:C → A:T transitions, a J-shaped association was
bserved with smoking frequency. The incidence rate ratio was
ignificantly decreased for the lowest category of frequency (RR




d number of colorectal cancer cases for the different smoking variables.
he highest category (RR 1.43; 95% CI 0.83–2.45). There were
o significant associations between risk for colorectal cancer
ith specific G:C → A:T transitions and smoking status, dura-
ion, pack years, age at first exposure, years since cessation,
nhalation or filter usage.
The analyses described above were also conducted for colon,
ectosigmoid and rectum cancer separately, and there were no
pparent differences in associations with smoking variables
etween various sites of the colorectal tract, although in some
ubgroups the numbers of cases were too small to draw defi-
ite conclusions. Therefore, the data for the various sites are not
hown and discussed any further.
In general, associations with the risk for wild-type KRAS col-
rectal tumors appeared stronger in men (Table 4) than in the
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Table 3
Adjusteda incidence rate ratios (RR) and corresponding 95% CI for colorectal cancer with G:C>T:A transversions and G:C > A:T transitions
Cigarette smoking variable Personyears
subcohortb
Colorectal cancer with G:C > T:A transversions Colorectal cancer with G:C > A:T transitions
Nc RR 95% CI N RR 95% CI
Smoking status
Never smoker 9,896 25 1.00 Reference 40 1.00 Reference
Ex-smoker 10,502 28 0.95 0.49–1.85 63 1.16 0.72–1.86
Current smoker 8,181 19 0.84 0.43–1.66 28 0.70 0.41–1.21
Frequency (cigarettes/day)
<10 5,002 19 1.35 0.72–2.56 9 0.44 0.21–0.94
10–20 6,028 12 0.59 0.27–1.31 29 1.11 0.62–2.00
>20 6,605 12 0.50 0.23–1.10 43 1.43 0.83–2.45
p-Trend 0.03 0.08
Duration (years)
<20 3,288 8 0.98 0.44–2.19 12 0.89 0.45–1.76
20–40 8,636 20 0.81 0.40–1.63 51 1.23 0.76–1.96
>40 6,389 17 0.71 0.34–1.50 28 0.70 0.39–1.26
p-Trend 0.35 0.40
Pack years
<9 4,905 14 1.09 0.56–2.15 13 0.68 0.35–1.29
10–30 7,336 15 0.63 0.29–1.36 34 1.04 0.60–1.81
>30 5,141 13 0.68 0.31–1.50 34 1.29 0.71–2.32
p-Trend 0.22 0.32
Age at first exposure (years)
<17 7,170 24 1.40 0.62–3.20 37 1.03 0.58–1.82
17–21 7,310 16 0.93 0.44–1.99 39 1.14 0.68–1.93
>21 3,980 6 0.56 0.22–1.40 15 0.80 0.43–1.48
p-Trend 0.13 0.71
Years since cessation (years)
<10 1,1830 28 0.82 0.43–1.58 50 0.85 0.53–1.38
10–30 5,873 17 1.02 0.48–2.13 38 1.28 0.75–2.18
>30 924 1 0.36 0.05–2.66 3 0.63 0.19–2.06
p-Trend 0.65 0.58
Inhalation
No 5,354 16 1.01 0.51–1.99 20 0.76 0.43–1.32
Yes 12,874 29 0.77 0.39–1.52 66 1.05 0.63–1.75
Filter usage
Filter-tipped 5,043 16 1.19 0.62–2.29 19 0.92 0.52–1.64
Non-filter-tipped 8,892 20 0.53 0.26–1.07 50 1.21 0.70–2.10



























b Personyears are estimated from the subcohort.
c Missing values of smoking characteristics gave rise to diminished personye
otal group as presented in Table 2. Associations with smok-
ng variables were absent for KRAS-mutated colorectal tumors
n men and for both end points in women (Table 4). In men,
he risk of KRAS wild-type colorectal tumors was increased
ignificantly in ex-smokers compared with never smokers (RR
.79, 95% CI 1.00–3.20), whereas for current smokers no sig-
ificantly increased risk was observed compared with never
mokers (RR 1.23, 95% CI 0.66–2.31). There was a signifi-
ant trend for increased KRAS wild-type colorectal cancer risk
ith increasing frequency of cigarette smoking in men (p-
rend = 0.02). For men smoking more than 20 cigarettes/day,
ompared with never smokers, the RR was 1.91, which was
tatistically significant (95% CI 1.03–3.52). For men inhal-
ng cigarette smoke versus never smokers, the RR for KRAS





d number of colorectal cancer cases for the different smoking variables.
ignificantly (RR 1.69, 95% CI 0.94–3.04, not shown in the
able).
For ex-smokers, both frequency and duration of smoking
ere associated with an increased risk for wild-type KRAS col-
rectal tumors, when compared with never smokers, although
his was not statistically significant (Table 5). Smoking more
han 20 cigarettes/day versus never smoking was associated with
35 percent increased risk of KRAS wild-type tumors (95% CI
.92–1.99 and p-trend = 0.09). Smoking cigarettes for more than
0 years was associated with a 44% increased risk of KRAS
ild-type tumors (95% CI 0.89–2.33, p-trend = 0.07). Althoughhe risk for mutated KRAS tumors was also elevated, although
ot statistically significantly, in ex-smokers who smoked more
han 20 cigarettes/day versus never smokers, there was no clear
rend (RR 1.40, 95% CI 0.84–2.33, p-trend = 0.22). In current
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Table 4
Sex-specific adjusteda incidence rate ratios (RR) and corresponding 95% CI for colorectal cancer with wild-type and mutated KRAS gene tumors according to
cigarette smoking status, frequency and duration
Cigarette smoking variable Personyears
subcohortb
Colorectal cancer–wild-type KRAS Colorectal cancer–mutated KRAS
Nc RR 95% CI Nc RR 95% CI
Men
Smoking status
Never smoker 1366 14 1.00 Reference 11 1.00 Reference
Ex-smoker 7444 147 1.79 1.00–3.20 85 1.20 0.61–2.33
Current smoker 5036 64 1.23 0.66–2.31 35 0.78 0.39–1.58
Frequency (cigarettes/day)
<10 2294 34 1.33 0.69–2.57 21 1.02 0.48–2.19
10–20 4236 66 1.48 0.80–2.76 35 0.93 0.46–1.90
>20 5148 97 1.91 1.03–3.52 53 1.17 0.58–2.36
p-Trend 0.02 0.57
Duration (years)
<20 1758 29 1.77 0.90–3.48 15 1.15 0.52–2.58
20–40 5545 100 1.72 0.95–3.12 65 1.31 0.67–2.58




Never smoker 8530 112 1.00 Reference 61 1.00 Reference
Ex-smoker 3058 41 1.09 0.74–1.62 22 1.10 0.67–1.82
Current smoker 3146 31 0.75 0.48–1.17 14 0.67 0.35–1.28
Frequency (cigarettes/day)
<10 2708 29 0.89 0.57–1.41 13 0.75 0.40–1.40
10–20 1791 28 1.26 0.80–1.97 13 1.18 0.63–2.19
>20 1457 14 0.69 0.38–1.25 7 0.68 0.28–1.64
p-Trend 0.60 0.57
Duration (years)
<20 1530 19 1.04 0.61–1.76 6 0.63 0.26–1.49
20–40 3091 36 0.96 0.63–1.46 18 0.96 0.55–1.68
>40 1419 16 0.79 0.46–1.36 10 0.94 0.46–1.91
p-Trend 0.48 0.79
































b Personyears are estimated from the subcohort.
c Missing values of smoking characteristics gave rise to diminished personye
mokers, there was no increased risk for wild-type or mutated
RAS tumors according to frequency or duration of smoking.
or mutated KRAS tumors, a slight protective effect was even
bserved in current smokers with frequency (p-trend = 0.06)
nd duration (p-trend = 0.05) of smoking. However, we have to
cknowledge that the number of cases were low in the current
moking group of cases with mutated KRAS tumors. Specifi-
ally, since people generally started smoking at a very early age,
he number of current smokers who smoked less than 10 years
as rare.
. Discussion
In the Netherlands Cohort Study on diet and cancer (NLCS)
e observed that current smoking was not associated with theisk for overall colorectal cancer, colorectal cancer with wild-
ype KRAS tumors or colorectal cancer with mutated KRAS
umors. Former smoking, frequency of cigarette smoking and





d number of colorectal cancer cases for the different smoking variables.
f colorectal cancer overall and with colorectal cancer with a
ild-type KRAS gene compared to never smoking, whereas asso-
iations were not apparent with respect to the risk for colorectal
ancer with mutated KRAS tumors. The associations with wild-
ype KRAS tumors appeared strongest for men and ex-smokers
nd were not apparent for women and current smokers. Further-
ore, no clear associations were observed between smoking
nd colorectal cancer with specific G:C → T:A transversions
r G:C → A:T transitions in KRAS. In contrast to what we
xpected, smoking was not associated with the risk for colorectal
ancer with KRAS oncogene mutations.
Few studies have looked at cigarette smoking and colorec-
al cancer while assessing KRAS mutation status. A summary
f the studies is given in Table 6. Regarding risk for KRAS-
utated tumors, none of the four studies showed a significantssociation between cigarette smoking and risk for colon car-
inomas or colorectal adenomas with mutated KRAS [19–22].
his is in line with our observations that none of the investigated
igarette-smoking variables are associated with the risk for col-
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Table 5
Adjusteda incidence rate ratios (RR) and corresponding 95% CI for colorectal cancer with wild-type and mutated KRAS gene tumors according to cigarette smoking
frequency and duration for ex-smokers and current smokers separately
Cigarette smoking variable Personyears
subcohortb
Colorectal cancer—wild-type KRAS Colorectal cancer—mutated KRAS
Nc RR 95% CI Nc RR 95% CI
Ex-smokersd
Frequency (cigarettes/day)
Never smoker 9896 126 1.00 Reference 72 1.00 Reference
<10 3172 45 1.12 0.77–1.62 25 1.03 0.63–1.68
10–20 3130 62 1.41 0.96–2.08 29 1.07 0.61–1.85
>20 3858 73 1.35 0.92–1.99 48 1.40 0.84–2.33
p-Trend 0.09 0.22
Duration (years)
Never smoker 9896 126 1.00 Reference 72 1.00 Reference
<20 2843 42 1.25 0.84–1.85 15 0.76 0.42–1.38
20–40 5946 108 1.32 0.96–1.83 72 1.40 0.91–2.16




Never smoker 9896 126 1.00 Reference 72 1.00 Reference
<10 1830 18 0.80 0.47–1.38 9 0.64 0.31–1.33
10–20 2898 32 0.94 0.59–1.51 19 0.82 0.45–1.49
>20 2748 38 1.09 0.71–1.68 12 0.48 0.24–0.98
p-Trend 0.80 0.06
Duration (years)
Never smoker 9896 126 1.00 Reference 72 1.00 Reference
<20 445 6 1.03 0.42–2.53 6 1.79 0.73–4.39
20–40 2690 28 0.95 0.59–1.51 11 0.61 0.31–1.20
>40 4981 59 0.85 0.58–1.26 31 0.61 0.35–1.06
p-Trend 0.44 0.05
a RRs are adjusted for age (years), sex, family history of colorectal cancer (yes/no), body mass index (kg/m2), alcohol and coffee consumption (g/day).










































Missing values of smoking characteristics gave rise to diminished personye
d In analyses for ex-smokers all current smokers were deleted from the analy
e In analyses for current smokers all ex-smokers were deleted from the analy
rectal carcinomas with mutated KRAS. However, in contrast to
ur study, the reported risks in the other studies in Table 6 are
lightly elevated, although they never reach statistical signifi-
ance.
We expected smoking variables to be associated with tumors
arboring specific point mutations in KRAS since genotoxic
ompounds of cigarette smoke have been shown to induce spe-
ific G:C → A:T and G:C → T:A mutations in RAS oncogenes in
odents. The only finding from our study that fits this hypothesis
s the non-significantly elevated risk for tumors with G:C > A:T
ransitions with smoking more than 20 cigarettes a day ver-
us never smoking. However, the overall association between
moking frequency and tumors with G:C > A:T transitions had a
-shape, and a significant inverse trend with smoking frequency
as observed for tumors with G:C → T:A transversions. Finally,
e expected an association with long-term smoking, thus smok-
ng duration, but this was not observed. Overall this leaves us to
onclude that there is no clear association between smoking vari-
bles and tumors with specific point mutations in KRAS. This
s in line with the findings from Slattery’s large case–control
tudy [19] in which no associations between smoking and risks





d number of colorectal cancer cases for the different smoking variables.
d never smokers form the reference category.
d never smokers form the reference category.
bserved when smoking ≥20 cigarettes/day was compared with
ot smoking (transitions OR 0.8, 95% CI 0.6–1.2, transversions
R 0.9, 95% CI 0.7–1.3). Diergaarde et al. [20] observed a
ositive association, although not significant, between cigarette
moking and tumors with G:C → T:A transversion mutations
n KRAS (KRAS transversions vs. controls; OR 2.2, 95% CI
.7–6.3). This association was not found between cigarette
moking and G:C → A:T transitions in KRAS (KRAS transitions
s. controls; OR 1.0, 95% CI 0.4–2.5) [20].
Surprisingly, the most consistent observation seems to be
n association between cigarette smoking and wild-type KRAS
olorectal tumors [19,21]. Two out of the four other studies
ummarized in Table 6 also suggest that associations between
igarette smoking and colorectal tumors are more pronounced
ith wild-type KRAS tumors. In line with our results, Slattery et
l.[19] observed an increased risk for having a wild-type KRAS
olon tumor when smoking ≥20 cigarettes/day (wild-type KRAS
s. controls; OR 1.3, 95% CI 1.1–1.6), compared with never
moking. Wark et al. [21] reported that both current and for-
er smokers, compared with never smokers, are at increased
isk for wild-type KRAS colorectal adenomas, but not mutated
RAS adenomas, in their case–control study (wild-type KRAS
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Table 6
Summary of studies of cigarette smoking and colorectal cancer
Author Reference Design # Cases/controls Outcome OR (95% CI)
Slattery et al. [19] Case–control study Mutated KRAS: 453 Colon carcinomas >20 cigarettes/day vs. none cigarettes/day:
Wild-type KRAS: 968 Mutated KRAS vs. controls: 1.2 (0.9–1.5)
Controls: 2404 Wild-type KRAS vs. controls: 1.3 (1.1–1.6)
KRAS transversion vs. controls: 0.9 (0.7–1.3)
KRAS transitions vs. controls: 0.8 (0.6–1.2)
Diergaarde et al. [20] Case–control study Mutated KRAS: 64 Colon carcinomas Ever smokers vs. never smokers:
Wild-type KRAS: 112 Mutated KRAS vs. controls: 1.4 (0.7–2.8)
Controls: 249 Wild-type KRAS vs. controls: 0.8 (0.5–1.4)
KRAS transversions: 31 KRAS transversion vs. controls: 2.2 (0.7–6.3)
KRAS transitions: 33 KRAS transitions vs. controls: 1.0 (0.4–2.5)
Wark et al. [21] Case–control study Mutated KRAS: 81 Colorectal adenomas Former smokers vs. never smokers:
Wild-type KRAS: 453 Mutated KRAS vs. controls: 1.20 (0.70–2.08)
Controls: 709 Wild-type KRAS vs. controls: 1.45 (1.08–1.96)
Current smokers vs. never smokers:
Mutated KRAS vs. controls: 1.27 (0.66–2.42)
Wild-type KRAS vs. controls: 2.04 (1.47–2.83)
Martinez et al. [22] Cross-sectional study Mutated KRAS: 120 Colorectal adenomas Past smokers vs. never smokers:
Wild-type KRAS: 558 Mutated KRAS vs. wild-type KRAS: 1.07 (0.67–1.70)
Current smokers vs. never smokers:
Mutated KRAS vs. wild-type KRAS: 1.17 (0.61–2.25)
Present study Cohort study Mutated KRAS: 81 Colorectal cancer Former smokers vs. never smokers:
Wild-type KRAS: 453 Mutated KRAS vs. never smokers: 1.15 (0.79–1.66)
Subcohort: 4083 Wild type KRAS vs. never smokers: 1.26 (0.96–1.66)
Current smokers vs. never smokers:















































s. controls; OR 2.04, 95% CI 1.47–2.83 and OR 1.45, 95% CI
.08–1.96, for current and former smokers, respectively, com-
ared with never smokers). In another case–control study on
igarette smoking and sporadic colon carcinomas by Diergaarde
t al. [20], ever-smokers were not at increased risk for having
umors with wild-type KRAS (wild-type KRAS vs. controls; OR
.8, 95% CI 0.5–1.4).
Our finding that the association of smoking variables with
ild-type KRAS tumors was strongest for men and not apparent
or women was also observed by Slattery et al. [19]. None of
he other studies reported sex-specific associations [20–22]. In
he present study, women smoked considerably less than men,
eaving relatively small numbers of female cases in different
ubgroups of smoking variables (see Table 4). This may have
nfluenced the results, but we should also note that there was no
ignificant effect modification by gender in this study. However,
t is worthwhile to further explore the strength of the associa-
ion between smoking and KRAS wild-type colorectal cancer in
omen in future studies.
Our finding that associations between smoking frequency and
uration and wild-type KRAS tumors was present in ex-smokers
ut not current smokers, all compared with never smokers, is
uzzling. Others have not reported such differences [19–22]. In
ur population, most people who ever smoked were ex-smokers.
any of these ex-smokers had smoked at a high frequency and
or a long time. Therefore, their lifetime exposure to smoking





Wild type KRAS vs. never smokers: 0.86 (0.62–1.18)
ancer risk. The lack of association among the current smok-
rs may reflect that this is a group of subjects that did not quit
moking because of smoking related ill-health and may there-
ore be less sensitive to the effects of smoking on colorectal
ancer than the ex-smokers. However, it should be noted that
he associations of the ex-smoking group were not statistically
ignificant and that further research is warranted to tease out
otential differential effects of ex- and current smokers on the
isk for colorectal cancer, especially wild-type KRAS tumors.
Many years are needed to develop colorectal cancer after ini-
iation. In this period, carcinogens from cigarette smoke cause
rreversible genetic damage in the colorectal mucosa. Giovan-
ucci et al. [23,24] suggested that the long lag time between
xposure to cigarette smoke and occurrence of colorectal cancer
s a possible explanation for smoking being a risk for colorec-
al adenomas but not for colorectal cancer. In the present study,
4% of the smokers had smoked for 20 years or more, 33% had
moked for 40 years or more and 43% started before the age of
9. These figures are high enough to assume that smoking could
ave caused colorectal cancer within the timeframe of this cohort
tudy.
Our results indicate that smoking is not associated with the
isk for colorectal cancer with KRAS oncogene mutations. How-
ver, smoking may be an early event in the development of
olorectal cancers that arise through other underlying genetic
athways, such as mutations in the adenomatous polyposis coli
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f hMLH1 expression [20,25–27]. Recently published results
rom the large case–control study discussed previously [19] sug-
est that smoking is related to CpG island methylator phenotype
CIMP) and V600E BRAF mutations in colon cancer, rather than
ith microsatellite-unstable cancer [28]. This could explain our
esults with regard to KRAS wild-type tumors, since KRAS muta-
ions are rare in tumors with CIMP and/or BRAF mutations [29].
In contrast to case–control studies, the smoking habits of
ll subjects in this study were reported before the disease was
iagnosed. Information bias, i.e. changes in smoking habits or
hange in report of smoking habits is therefore almost com-
letely avoided in a prospective cohort study like this one. A
hange in smoking habits of subjects with pre-clinical colorec-
al cancer at the time of completing the baseline questionnaire
emains possible. The completeness of follow-up together with
he prospective nature of a cohort study reduced the potential
or selection bias to a minimum. Underreporting of smoking
abits because of social desirability remains possible. This could
ead to non-differential misclassification of smoking habits. In
his study, smoking characteristics are based on active smoking
abits. Unfortunately, the effect of passive smoking is there-
ore not estimated. This may have attenuated the associations
bserved.
In conclusion, this study indicates that smoking is not asso-
iated with the risk for colorectal cancer with specific mutations
n the KRAS gene. The study suggests that smoking may be
ssociated with the risk for a specific molecular subgroup of
olorectal cancer characterized by wild-type KRAS tumors. For
n ex-smoker, smoking frequency and inhalation seemed to be
ssociated with an increased risk for colorectal cancer with wild-
ype KRAS gene tumors, especially in men. Future studies should
ease out whether there are other molecular characteristics of the
RAS wild-type tumors that may better explain the association
ith cigarette smoking.
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